title: [Novobiocin inhibits angiogenesis and shows synergistic effect with vincristine].
abstract: OBJECTIVE
  To study the anti-angiogenic activity of novobiocin and its mechanism of action.
  
  
  METHODS
  The anti-angiogenic activity of novobiocin was determined using chick embryo chorioallantoic membrane(CAM) assay. MTT assay, zymography and related assays were used to observe the effects of drugs on bovine aorta endothelial cells and human pulmonary carcinoma PG cells.
  
  
  RESULTS
  Novobiocin at the doses of 100 and 200 micrograms/egg inhibited angiogenesis by 31.6% and 68.7% in CAM, respectively. The combination of novobiocin and vincristine enhanced the anti-angiogenic effect. Novobiocin inhibited the proliferation of bovine aortic endothelial cells in a concentration-dependent manner. In addition, novobiocin suppressed MMP-2 secretion, migration, and tube formation of endothelial cells. As determined by MTT assay, novobiocin in combination with vincristine displayed synergistic effect on the proliferation of PG cells,
  
  
  CONCLUSIONS
  This study demonstrates that novobiocin is active in suppressing angiogenesis and the anti-angiogenic activity may be enhanced by combination with vincristine. The anti-angiogenic activity of novobiocin may be related, at least in part, to its inhibition of cell proliferation, cell migration, tube formation and secretion of matrix metalloproteinases.
authors.affiliation: Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100050, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Yang
authors.forename: Min
authors.initials: M
authors.lastname: Jiang
authors.forename: Yong-su
authors.initials: YS
authors.lastname: Zhen
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D002417:Cattle; D002455:Cell Division / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D002642:Chick Embryo; D004357:Drug Synergism; D042783:Endothelial Cells / Q000166:cytology*; D006801:Humans; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism*; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D009675:Novobiocin / Q000494:pharmacology*; D014407:Tumor Cells, Cultured; D014750:Vincristine / Q000494:pharmacology
chemical_list: D020533:Angiogenesis Inhibitors; D000972:Antineoplastic Agents, Phytogenic; D009675:Novobiocin; D014750:Vincristine; D020778:Matrix Metalloproteinase 2